Latanoprost
- Generic Name
- Latanoprost
- Brand Names
- Iyuzeh, Rocklatan, Xalacom, Xalatan, Xelpros, Catiolanze
- Drug Type
- Small Molecule
- Chemical Formula
- C26H40O5
- CAS Number
- 130209-82-4
- Unique Ingredient Identifier
- 6Z5B6HVF6O
- Background
Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment. It has been found to be well-tolerated and its use does not normally result in systemic adverse effects l...
- Indication
Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension. It is available as monotherapy or in a combination product with netarsudil or timolol.
...
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Ocular Hypertension, Open Angle Glaucoma (OAG)
- Associated Therapies
- -
Microneedling and Latanoprost in Acrofacial Vitiligo
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 70
- Registration Number
- NCT03611348
Eyenovia MiDD Usability Study
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Eyenovia Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03480906
- Locations
- 🇵🇦
Clinica de Ojos Orillac-Calvo, Panama City, Panama
A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 146
- Registration Number
- NCT03419975
- Locations
- 🇰🇷
Chan Yun, Kim, Seoul, Korea, Republic of
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
- Conditions
- Interventions
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Dr. David Yan
- Target Recruit Count
- 60
- Registration Number
- NCT02792803
- Locations
- 🇨🇦
Opthalmis Diagnostic Services, Toronto, Ontario, Canada
Blood Flow of Ophthalmic Artery and Glaucoma
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Umeå University
- Target Recruit Count
- 125
- Registration Number
- NCT02656979
- Locations
- 🇸🇪
Department of Clinical Science, Ophthalmology, Umeå University, Umeå, Västerbotten, Sweden
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT02622334
- Locations
- 🇺🇸
Cornerstone Eye Care, Div of Cornerstone Health Care, High Point, North Carolina, United States
🇸🇬Singapore National Eye Centre; Glaucoma Department, Singapore, Singapore
🇺🇸New York Eye and Ear Infirmary of Mt. Sinai; New York Glaucoma Research Institute, New York, New York, United States
28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension
- Conditions
- Interventions
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 54
- Registration Number
- NCT02531152
- Locations
- 🇺🇸
Investigational Site Number 840001, Inglewood, California, United States
🇺🇸Investigational Site Number 840005, Roswell, Georgia, United States
🇺🇸Investigational Site Number 840004, St Joseph, Michigan, United States
Pupillary Response After Glaucoma Medication
- Conditions
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Glostrup University Hospital, Copenhagen
- Target Recruit Count
- 21
- Registration Number
- NCT02522039
- Locations
- 🇩🇰
Glostrup University Hospital, Glostrup, Denmark
Stop Retinal Ganglion Cell Dysfunction Study
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 500
- Registration Number
- NCT02390284
- Locations
- 🇺🇸
Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States
Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients
- Conditions
- Interventions
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 242
- Registration Number
- NCT02278614
- Locations
- 🇫🇷
Laboratoires Thea, Clermont ferrand, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.